The U.S. District Court for the District of Columbia has ruled in favor of the 2020 Rule established by the Centers for Medicare and Medicaid Services (CMS) regarding Organ Procurement Organizations (OPOs). This decision affects how OPOs are certified to operate and could have significant implications for organ donation practices across the United States.

The case, New England Donor Services, Inc. v. United States Department of Health and Human Services, was filed by several OPOs who challenged the legality of the 2020 Rule, arguing it exceeded the agency's authority and was arbitrary and capricious. The ruling, issued by Judge Sparkle L. Sooknanan, confirms the legality of the 2020 Rule and allows CMS to enforce its new certification standards for OPOs.

This ruling is crucial as it impacts the operation of OPOs, which are responsible for acquiring, preserving, and transporting donated organs. The decision ensures that the new metrics for evaluating OPO performance will remain in place, which aims to improve organ donation rates and ultimately save more lives.

Background

The plaintiffs in this case include New England Donor Services, We Are Sharing Hope SC, and Donor Network of Arizona, all of which are OPOs operating in various states. They filed the lawsuit in December 2025, shortly before the implementation of the 2020 Rule, which introduced new performance metrics for OPOs. The plaintiffs claimed that the rule forced them to compete for certification and service areas, which they argued was not allowed under the law.

The 2020 Rule was established in response to an Executive Order from former President Donald Trump aimed at modernizing the organ recovery and transplantation systems. The rule changed how OPOs are evaluated, replacing previous metrics with new ones that focus on donation and transplantation rates. The plaintiffs contended that these changes exceeded CMS's statutory authority and were not grounded in sufficient evidence.

The Ruling

The court ruled that it had jurisdiction to hear the case and that the 2020 Rule was lawful under the Administrative Procedure Act (APA). Judge Sooknanan stated, "The agency acted well within its statutory authority in promulgating the rule by exercising discretion conferred by Congress." The court found that the rule was not arbitrary and capricious, acknowledging that while reasonable minds might differ on policy decisions, it was not the court's role to substitute its judgment for that of the agency.

The ruling emphasized that the certification process for OPOs is critical to the effectiveness of the organ transplantation system. The court noted that the changes made by CMS aimed to improve transparency and accountability in organ procurement, which is essential in addressing the ongoing shortage of donated organs.

Impact

This ruling has significant implications for the future of organ donation in the United States. By upholding the 2020 Rule, the court ensures that OPOs will be held to new performance standards that aim to increase the number of organs available for transplant. This could lead to more lives being saved as the system becomes more efficient and effective.

The decision also sets a precedent for future challenges against agency regulations. It reinforces the idea that courts will defer to agency expertise in matters where the agency has been granted discretion by Congress. This ruling may discourage other OPOs or organizations from challenging similar regulations in the future.

What's Next

The plaintiffs may consider appealing the decision, but details regarding any potential appeal were not available in the court filing. The outcome of this case may also influence related cases involving OPO regulations and the broader organ donation system.